BR112016002872A2 - derivados de 1 h-pirazolo[3,4-b]piridina e composições farmacêuticas dos mesmos para o tratamento de distúrbios proliferativos - Google Patents

derivados de 1 h-pirazolo[3,4-b]piridina e composições farmacêuticas dos mesmos para o tratamento de distúrbios proliferativos

Info

Publication number
BR112016002872A2
BR112016002872A2 BR112016002872A BR112016002872A BR112016002872A2 BR 112016002872 A2 BR112016002872 A2 BR 112016002872A2 BR 112016002872 A BR112016002872 A BR 112016002872A BR 112016002872 A BR112016002872 A BR 112016002872A BR 112016002872 A2 BR112016002872 A2 BR 112016002872A2
Authority
BR
Brazil
Prior art keywords
treatment
diseases
pharmaceutical compositions
pyrazolo
prophylaxis
Prior art date
Application number
BR112016002872A
Other languages
English (en)
Inventor
Sara Butler Anna
Antoine Schmitt Benoît
Marie-Emilie Bonnaterre Florence
James Dykes Graeme
Huck Jacques
Blanc Javier
Raymond Maurice Sanière Laurent
Nicolas Alain Beaumont Stéphane
Original Assignee
Galapagos Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galapagos Nv filed Critical Galapagos Nv
Publication of BR112016002872A2 publication Critical patent/BR112016002872A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

a presente invenção refere-se a compostos de acordo com a fórmula (i): em que r1, r2, r3, r4, l, e x são conforme definido no pre-sente documento. a presente invenção refere-se a compostos, méto-dos para sua produção, composições farmacêuticas que compreen-dem os mesmos, e seu uso na profilaxia e/ou tratamento de condições inflamatórias, diabetes tipo 2, doenças neurológicas e/ou neurodege-nerativas, doenças autoimunes, doenças proliferativas (em particular doenças metastáticas e/ou câncer), doenças associadas à angiogêne-se anormal, degradação de cartilagem, e/ou ruptura de homeostase de cartilagem, em particular na profilaxia e/ou tratamento de câncer. a presente invenção também descreve métodos de tratamento que utili-zam os mesmos compostos, para a profilaxia e/ou tratamento de ditas doenças ao administrar o composto da invenção.
BR112016002872A 2013-08-23 2014-08-18 derivados de 1 h-pirazolo[3,4-b]piridina e composições farmacêuticas dos mesmos para o tratamento de distúrbios proliferativos BR112016002872A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1315072.7A GB201315072D0 (en) 2013-08-23 2013-08-23 Novel compounds and pharmaceutical compositions thereoffor the treatment of proliferative disorders
PCT/EP2014/067574 WO2015024905A1 (en) 2013-08-23 2014-08-18 Derivatives of 1 h-pyrazolo[3,4-b]pyridine and pharmaceutical compositions thereof for the treatment of proliferative disorders

Publications (1)

Publication Number Publication Date
BR112016002872A2 true BR112016002872A2 (pt) 2017-08-01

Family

ID=49302102

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016002872A BR112016002872A2 (pt) 2013-08-23 2014-08-18 derivados de 1 h-pirazolo[3,4-b]piridina e composições farmacêuticas dos mesmos para o tratamento de distúrbios proliferativos

Country Status (16)

Country Link
US (1) US9062051B2 (pt)
EP (1) EP3036234A1 (pt)
JP (1) JP2016528269A (pt)
KR (1) KR20160040301A (pt)
CN (1) CN105473590A (pt)
AR (1) AR097339A1 (pt)
AU (1) AU2014310652A1 (pt)
BR (1) BR112016002872A2 (pt)
CA (1) CA2920991A1 (pt)
GB (1) GB201315072D0 (pt)
IL (1) IL243739A0 (pt)
MX (1) MX2016002078A (pt)
PH (1) PH12016500173A1 (pt)
SG (1) SG11201601157XA (pt)
TW (1) TW201536783A (pt)
WO (1) WO2015024905A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111620868B (zh) * 2020-05-28 2021-08-31 爱斯特（成都）生物制药股份有限公司 一种1H-吡唑并[3,4-b]吡啶-3-甲醛的制备方法
EP4215533A1 (en) * 2020-09-16 2023-07-26 Axceso Biopharma Co., Ltd. Pyrimidopyrimidinone compound and pharmaceutical composition comprising same

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100113415A1 (en) * 2008-05-29 2010-05-06 Rajapakse Hemaka A Epha4 rtk inhibitors for treatment of neurological and neurodegenerative disorders and cancer
US8846673B2 (en) * 2009-08-11 2014-09-30 Bristol-Myers Squibb Company Azaindazoles as kinase inhibitors and use thereof
KR20130077390A (ko) * 2011-12-29 2013-07-09 제이더블유중외제약 주식회사 단백질 키나아제 저해활성을 가지는 6-아미노-3-카복스아미도인다졸 유도체

Also Published As

Publication number Publication date
KR20160040301A (ko) 2016-04-12
IL243739A0 (en) 2016-04-21
AU2014310652A1 (en) 2016-03-03
PH12016500173A1 (en) 2016-04-25
MX2016002078A (es) 2016-06-23
JP2016528269A (ja) 2016-09-15
CN105473590A (zh) 2016-04-06
EP3036234A1 (en) 2016-06-29
US9062051B2 (en) 2015-06-23
WO2015024905A1 (en) 2015-02-26
TW201536783A (zh) 2015-10-01
US20150080391A1 (en) 2015-03-19
AR097339A1 (es) 2016-03-09
GB201315072D0 (en) 2013-10-02
SG11201601157XA (en) 2016-03-30
CA2920991A1 (en) 2015-02-26

Similar Documents

Publication Publication Date Title
BR112017022604A2 (pt) composto, composição farmacêutica, uso de um composto e de uma combinação, e, combinação
MX2018004175A (es) Derivado oxa espiro, su metodo de preparacion, y sus aplicaciones en medicinas.
BR112015020998A2 (pt) compostos e composições farmacêuticas dos mesmos para o tratamento de distúrbios inflamatórios
BR112013001088A2 (pt) "derivados substituídos como inibidores a quinase de imidazoquinolina"
BR112013017779A2 (pt) derivados de oxazina e seu uso no tratamento de distúrbios neurológicos
GT201300179A (es) Derivados heterociclicos novedosos y su uso en el tratamiento de trastornos neurologicos
BR112014022000A8 (pt) compostos à base de pirazol[1,5-a]pirimidina, seu uso e composições que os compreende
BR112012015916A2 (pt) derivados de pirazina e seu uso no tratamento de distúrbios neurológicos
BR112015012555A2 (pt) derivados de benzimidazol como antagonistas de ep4
BR112016003229A8 (pt) composto, composição farmacêutica, e, uso de um composto ou de uma composição farmacêutica
BR112018071408A2 (pt) “composto inibidor de rip2 quinase, composição farmacêutica, usos de um composto e de uma combinação, e, combinação
BR112013002112A2 (pt) composto, composição farmacêutica, e, uso de um composto, ou de um respectivo sal farmaceuticamente aceitável ou n-óxido, ou um solvato ou hidrato do mesmo, ou de uma composição
EA201490888A1 (ru) Новые производные пурина и их применение для лечения заболевания
BR112013000059A2 (pt) derivados de piperidina e seus usos para o tratamento de distúrbios metabólicos
BR112016005914A2 (pt) derivados de 1-(4-pirimidinil)-1h-pirrolo[3,2-c]piridina como inibidores de nik
BR112016011170A8 (pt) derivados de heteroaril ácido butanoico, seus usos, combinação e composição farmacêutica
ECSP15000868A (es) Derivados de estra–1,3,5(10),16–tetraeno 3–sustituidos, métodos para su preparación, preparaciones farmacéuticas que los contienen, así como su uso para la preparación de medicamentos
CO7111276A2 (es) Compuestos de 3,5 disustituido-3h imidazo[4,5-b] piridina y 3,5 disustituido - 3h-[1,2,3] triaolo [4,5-b] piridina novedosos como moduladores d proteínas cinasas c-met
BR112014001908A2 (pt) derivados aza heterocíclicos substituídos
BR112017012588A2 (pt) compostos heteroaril-heteroarila bicíclicos de ácido benzoico como agonistas de receptores beta do ácido retinoico (rarbeta)
BR112017002498A2 (pt) derivados de 6-alquil-piridina como miméticos de smac
PH12018500650A1 (en) New imidazo [4,5-b] pyridine derivatives, a process for their preparation and pharmaceutical compositions containing them
PH12016500092B1 (en) New azabenzimidazole derivatives
BR112018007392A2 (pt) derivados de 6-[5-amino-6-(2-etoxietóxi)-imidazo[4,5-b]piridin-3-il]-nicotinonitrila e seu uso como inibidores de irak
BR112018073219A2 (pt) Composto de fórmula i, composição farmacêutica, processo para síntese destescompostos e uso dos mesmos

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]